Biopharmaceutical company Alvotech and global pharmaceutical company STADA Arzneimittel AG (“STADA”) today announced that ...
(Reuters) - AstraZeneca Plc said on Wednesday it plans to sell the European and Russian rights for a schizophrenia drug to ...
By Market Players: Reckitt Benckiser Group Plc , GlaxoSmithKline Plc. , Bayer AG , Nuun and Company Inc. , Bristol-Myers Squibb Co (UPSA Laboratories) , Herbalife International of America, Inc. , ...
Takeda Pharmaceutical Company Limited (NYSE:TAK) ("Takeda") today announced that it has entered into an agreement to divest a portfolio of select products to STADA Arzneimittel AG ("STADA"), an ...
(Reuters) - Takeda Pharmaceutical Co Ltd (4502.T), Japan’s largest drugmaker, said on Tuesday it would sell some of its ...
(RTTNews) - Takeda Pharmaceutical Company Limited (TKPYY.PK) announced Tuesday that it has entered into an agreement to divest a portfolio of select products to STADA Arzneimittel AG for a total ...
Germany's Cheplapharm Arzneimittel bought the rights to sell schizophrenia and bipolar drugs Seroquel and Seroquel XR in ...
KUALA LUMPUR, Nov 5 -- Takeda Pharmaceutical Company Limited (Takeda) has entered into an agreement to divest a portfolio of select products to pharmaceutical company, STADA Arzneimittel AG (STADA) ...
AstraZeneca has signed a 239 million US dollar (£186 million) deal to sell a revenue-generating anti-psychotic drug as it bids to move away from mature treatments and invest in innovation.
Stada Arzneimittel reeled in $1.6 billion in 2014 generics revenue, virtually identical to its 2013 revenue, but not good enough to keep the No. 11 spot. EvaluatePharma clocks this as a 1% decrease in ...
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it has entered into an agreement to divest a portfolio of select products to STADA Arzneimittel AG (“STADA”), ...